Healthcare provider profile · identity verified

Srinivasa Eswarapu, MD

Internal Medicine · BELLEVILLE, NJ · NPI 1346215225

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	509	144
Amlodipine Besylate	Amlodipine Besylate	277	84
Rosuvastatin Calcium	Rosuvastatin Calcium	264	81
Metformin Hcl	Metformin Hcl	199	60
Levothyroxine Sodium	Levothyroxine Sodium	174	41
Metoprolol Succinate	Metoprolol Succinate	173	46
Fluticasone Propionate	Fluticasone Propionate	161	61
Jardiance	Empagliflozin	154	37
Albuterol Sulfate Hfa	Albuterol Sulfate	149	47
Losartan Potassium	Losartan Potassium	123	41
Omeprazole	Omeprazole	112	33
Carvedilol	Carvedilol	108	35
Diclofenac Sodium	Diclofenac Sodium	104	37
Gabapentin	Gabapentin	94	28
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	86	30
Pantoprazole Sodium	Pantoprazole Sodium	84	28
Furosemide	Furosemide	83	28
Tamsulosin Hcl	Tamsulosin Hcl	72	19
Eliquis	Apixaban	70	19
Valsartan	Valsartan	67	21
Clopidogrel	Clopidogrel Bisulfate	66	23
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	64	17
Hydrochlorothiazide	Hydrochlorothiazide	63	20
Lisinopril	Lisinopril	62	16
Allopurinol	Allopurinol	61	16
Naproxen	Naproxen	60	41
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	54	suppressed
Azithromycin	Azithromycin	53	48
Alprazolam	Alprazolam	50	12
Trazodone Hcl	Trazodone Hcl	48	21
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	48	16
Ezetimibe	Ezetimibe	47	15
Januvia	Sitagliptin Phosphate	46	suppressed
Alendronate Sodium	Alendronate Sodium	44	16
Janumet	Sitagliptin Phos/Metformin Hcl	44	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	44	21
Promethazine Hcl	Promethazine Hcl	44	33
Spironolactone	Spironolactone	44	13
Escitalopram Oxalate	Escitalopram Oxalate	43	13
Lactulose	Lactulose	43	15
Memantine Hcl	Memantine Hcl	42	14
Mometasone Furoate	Mometasone Furoate	42	31
Zolpidem Tartrate	Zolpidem Tartrate	42	suppressed
Mounjaro	Tirzepatide	40	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	39	13
Tradjenta	Linagliptin	39	suppressed
Simvastatin	Simvastatin	37	11
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	36	suppressed
Jentadueto	Linagliptin/Metformin Hcl	36	suppressed
Levetiracetam	Levetiracetam	36	suppressed
Tramadol Hcl	Tramadol Hcl	35	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	34	11
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	33	12
Enalapril Maleate	Enalapril Maleate	33	suppressed
Mirtazapine	Mirtazapine	33	suppressed
Montelukast Sodium	Montelukast Sodium	33	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	33	suppressed
Celecoxib	Celecoxib	32	15
Entresto	Sacubitril/Valsartan	32	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	32	12
Farxiga	Dapagliflozin Propanediol	30	suppressed
Hydralazine Hcl	Hydralazine Hcl	30	suppressed
Potassium Chloride	Potassium Chloride	28	suppressed
Breo Ellipta	Fluticasone/Vilanterol	27	suppressed
Chlorthalidone	Chlorthalidone	27	suppressed
Ibuprofen	Ibuprofen	27	11
Duloxetine Hcl	Duloxetine Hcl	23	suppressed
Meclizine Hcl	Meclizine Hcl	23	12
Torsemide	Torsemide	23	suppressed
Xarelto	Rivaroxaban	22	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	21	suppressed
Sertraline Hcl	Sertraline Hcl	21	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	19	14
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	19	12
Donepezil Hcl	Donepezil Hcl	19	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	19	suppressed
Bumetanide	Bumetanide	18	suppressed
Clonidine Hcl	Clonidine Hcl	18	suppressed
Levemir Flexpen	Insulin Detemir	18	suppressed
Telmisartan	Telmisartan	18	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	17	suppressed
Dutasteride	Dutasteride	17	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	17	suppressed
Prednisone	Prednisone	17	13
Glyxambi	Empagliflozin/Linagliptin	16	suppressed
Irbesartan	Irbesartan	16	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	15	suppressed
Famotidine	Famotidine	15	suppressed
Glimepiride	Glimepiride	15	suppressed
Glipizide Er	Glipizide	15	suppressed
Meloxicam	Meloxicam	15	suppressed
Metformin Hcl Er	Metformin Hcl	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Rivastigmine	Rivastigmine	15	suppressed
Glipizide	Glipizide	14	suppressed
Hydrocortisone	Hydrocortisone	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Jentadueto Xr	Linagliptin/Metformin Hcl	14	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Phenobarbital	Phenobarbital	14	suppressed
Clobazam	Clobazam	13	suppressed
Lidocaine	Lidocaine	13	suppressed
Olmesartan-Amlodipine-Hctz	Olmesartan/Amlodipin/Hcthiazid	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Vemlidy	Tenofovir Alafenamide	13	suppressed
Ztlido	Lidocaine	13	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	12	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	12	suppressed
Hydrocodone-Ibuprofen	Hydrocodone/Ibuprofen	12	suppressed
Lacosamide	Lacosamide	12	suppressed
Novolog Flexpen	Insulin Aspart	12	suppressed
Pregabalin	Pregabalin	12	suppressed
Repaglinide	Repaglinide	12	suppressed
Latanoprost	Latanoprost	11	suppressed
Levocarnitine	Levocarnitine	11	suppressed
Ranolazine Er	Ranolazine	11	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	11	suppressed
Tizanidine Hcl	Tizanidine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error